Novo Nordisk A/S (NYSE:NVO) insider Eric S. Sprott bought 50,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were acquired at an average price of $8.34 per share, for a total transaction of $417,000.00.

Novo Nordisk A/S (NVO) opened at $49.84 on Wednesday. The stock has a market capitalization of $126,887.99, a price-to-earnings ratio of 21.73, a PEG ratio of 2.97 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $50.95.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/15/eric-s-sprott-acquires-50000-shares-of-novo-nordisk-as-nvo-stock.html.

NVO has been the topic of several recent analyst reports. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. BidaskClub downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Finally, BNP Paribas downgraded Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $55.00.

Hedge funds have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 6.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after buying an additional 150 shares during the last quarter. AlphaMark Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 1.1% in the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after buying an additional 30 shares during the last quarter. Zions Bancorporation boosted its stake in shares of Novo Nordisk A/S by 677.1% in the 3rd quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after buying an additional 2,485 shares during the last quarter. MUFG Americas Holdings Corp boosted its stake in shares of Novo Nordisk A/S by 100.0% in the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after buying an additional 1,500 shares during the last quarter. Finally, Cornerstone Advisors Inc. boosted its stake in shares of Novo Nordisk A/S by 1,220.2% in the 2nd quarter. Cornerstone Advisors Inc. now owns 3,525 shares of the company’s stock worth $151,000 after buying an additional 3,258 shares during the last quarter. Hedge funds and other institutional investors own 6.01% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.